Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from Türkiye.
Observational study in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
21 authors.
Umut Devrim BinayDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erzincan Binali Yıldırım University, 24100 Erzincan, Türkiye.ORCID 0000-0003-3841-9109
Faruk KarakeçiliDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erzincan Binali Yıldırım University, 24100 Erzincan, Türkiye.ORCID 0000-0002-7368-7187
Bilgehan AygenDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erciyes University, 38030 Kayseri, Türkiye.
Ayşin Kılınç TokerDepartment of Infectious Diseases and Clinical Microbiology, Kayseri City Hospital, University of Health Sciences, 38080 Kayseri, Türkiye.
İlhami ÇelikDepartment of Infectious Diseases and Clinical Microbiology, Kayseri City Hospital, University of Health Sciences, 38080 Kayseri, Türkiye.ORCID 0000-0002-2604-3776
Neşe DemirtürkDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Afyonkarahisar Health Sciences University, 03030 Afyonkarahisar, Türkiye.
Tuğçe Şimşek BozokDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Mersin University, 33343 Mersin, Türkiye.
Leyla DursunDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erciyes University, 38030 Kayseri, Türkiye.ORCID 0009-0005-5376-0825
Fethiye AkgülDepartment of Infectious Diseases and Clinical Microbiology, Batman Training and Research Hospital, 72070 Batman, Türkiye.
Güle ÇınarDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ankara University, 06230 Ankara, Türkiye.ORCID 0000-0002-7635-8848
Özgür GünalDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Samsun University, 55080 Samsun, Türkiye.ORCID 0000-0002-7744-4123
Ali AsanDepartment of Infectious Diseases and Clinical Microbiology, Bursa Yüksek İhtisas Training and Research Hospital, University of Health Sciences, 16310 Bursa, Türkiye.ORCID 0000-0002-8856-7356
Eyüp ArslanDepartment of Infectious Diseases and Clinical Microbiology, Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, University of Health Sciences, 34785 İstanbul, Türkiye.ORCID 0000-0002-5490-465X
Fatma Yılmaz KaradağDepartment of Infectious Diseases and Clinical Microbiology, Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, University of Health Sciences, 34785 İstanbul, Türkiye.ORCID 0000-0003-4657-5291
Orçun BarkayDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erzincan Binali Yıldırım University, 24100 Erzincan, Türkiye.ORCID 0000-0001-5347-7740
İrem AkdemirDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ankara University, 06230 Ankara, Türkiye.ORCID 0000-0001-5136-9148
Funda ŞimşekDepartment of Infectious Diseases and Clinical Microbiology, Prof. Dr. Cemil Taşçıoğlu City Hospital, University of Health Sciences, 34384 İstanbul, Türkiye.
Emine Türkoğlu YılmazDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Tokat Gaziosmanpaşa University, 60030 Tokat, Türkiye.
Zeynep Ravza EğilmezDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erciyes University, 38030 Kayseri, Türkiye.ORCID 0000-0003-2150-1077
Süda TekinDepartment of Infectious Diseases and Clinical Microbiology, Acıbadem Ataşehir Hospital, 34642 İstanbul, Türkiye.
The Viral Hepatitis Study Group Of The Turkish Society Of Clinical Microbiology And Infectious Diseases Klimik
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
The combination of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) is recommended as a salvage therapy for treatment-experienced chronic hepatitis C (CHC) patients. However, it is used in our country for treatment-naïve and treatment-experienced patients. This study aims to present real-world data from Türkiye on CHC patients treated with SOF/VEL/VOX. The present study was conducted by the Viral Hepatitis Study Group of the Turkish Society of Clinical Microbiology and Infectious Diseases (KLİMİK). It was a multicenter, retrospective, observational study. The data were collected from patients receiving SOF/VEL/VOX therapy at 12 medical centers in Türkiye between 1 June 2022 and 31 December 2024. The patients had received the treatment for 8 to 12 weeks. Of the 139 patients enrolled, 63.3% (
Indexed as
Antiviral AgentsCarbamatesHepatitis C, ChronicHeterocyclic Compounds, 4 or More RingsMacrocyclic CompoundsSofosbuvirSulfonamidesAdultAgedAminoisobutyric AcidsCyclopropanesDrug CombinationsDrug Therapy, CombinationFemaleHepacivirusHumansAminoisobutyric AcidsAntiviral AgentsCarbamatesCyclopropanesDrug CombinationsHeterocyclic Compounds, 4 or More RingsLactams, MacrocyclicLeucineMacrocyclic CompoundsProlineQuinoxalinesSofosbuvirsofosbuvir velpatasvir voxilaprevir drug combinationSulfonamidesvoxilaprevirhepatitis C treatmentreal-world datasofosbuvir/velpatasvir/voxilaprevir
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from Türkiye. · full record | Socratic